Suchergebnisse - "Ellis, Matthew"

PubPharm (60)

1

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination : A Phase 3 Randomized Clinical Trial

enthalten in: JAMA oncology | 2024

von Ma, C. | Suman, V. | Sanati, S. | +27

2

The uncharted role of HER2 mutant alleles in breast cancer

enthalten in: Oncotarget | 2023

von Kalra, R. | Lim, B. | Ellis, M. | +1

3

Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer

enthalten in: Cancer research | 2022

von Kalra, R. | Chen, C. | Wang, J. | +11

4

Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031)

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Suman, V. | Du, L. | Hoskin, T. | +6

5

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Ma, C. | Luo, J. | Freedman, R. | +22

6

A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy

enthalten in: Breast cancer research and treatment | 2021

von Polley, M. | Dickler, M. | Sinnwell, J. | +9

7

Assessment of Ki67 in Breast Cancer : Updated Recommendations From the International Ki67 in Breast Cancer Working Group

enthalten in: Journal of the National Cancer Institute | 2021

von Nielsen, T. | Leung, S. | Rimm, D. | +19

8

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

enthalten in: Nature communications | 2021

von Punturi, N. | Seker, S. | Devarakonda, V. | +8

9

Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial

enthalten in: Journal of the National Cancer Institute | 2021

von Albain, K. | Gray, R. | Makower, D. | +25

CommentIn: J Natl Cancer Inst. 2021 Apr 6;113(4):349-350. - PMID 32986842

10

Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer

enthalten in: Breast cancer research and treatment | 2021

von da Silva, L. | de Andrade, C. | Brenelli, F. | +11

1
2
3
4
5
6
Nächster »
[6]